UBX 362
Alternative Names: UBX-362Latest Information Update: 01 Mar 2024
At a glance
- Originator Ubix Therapeutics
- Class Antineoplastics
- Mechanism of Action Bcr-Abl tyrosine kinase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Chronic myeloid leukaemia